HUYA Bioscience International and China Medical City Forge Alliance to Help Develop China’s Pharmaceutical Industry

SAN DIEGO, June 28/PRNewswire/ --HUYA Bioscience International, a leader in globalizing China‘s pharmaceutical innovations, today announced a strategic partnership with the Taizhou National Medical Hi-tech Development Zone, also known as “China Medical City” (CMC). The alliance will combine both parties’ strengths in pharmaceutical product R&D and commercialization in order to promote China‘s pharmaceutical-biotech industry to the world-class level.

HUYA is one of the first companies to have recognized China‘s potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to enabling and accelerating the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research organizations throughout China and has pioneered in-licensing clinical stage compounds from China, utilizing its expertise to advance these compounds for global markets.

CMC, located in the Yangtze River Delta north of Shanghai, is the first national level industrial development zone dedicated to the medical and pharmaceutical industries. The hi-tech park has attracted to its campus many top universities, research institutes, commercial enterprises, and pioneer projects, such as stem cell research. The new CMC R&D Centers, including CAS Protein Engineering Research Center, Regional Food and Drug Inspection and Test Center, macromolecule and small molecule R&D platform facilities, and Vaccine Engineering Center, have earned a strong reputation.

Under the agreement, CMC and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by pharmaceutical companies residing in CMC. HUYA also will have the ability to globalize select programs from CMC through HUYA’s worldwide pharmaceutical partners.

“HUYA and CMC share the goals of advancing China‘s pharma-biotech industry and making its innovative products available to patients globally,” said Mireille Gingras, Ph.D., President and CEO of HUYA. “We are excited about collaborating with CMC to explore and maximize the value of the park’s resources.”

Yunyan Zhao, Deputy Director of CMC’s Administration Committee, commented, “CMC is committed to developing our country’s pharmaceutical and medical industries into a leading position in the world, and HUYA’s mission matches our aspirations. We look forward to building a mutually beneficial relationship with the HUYA team to enhance the R&D programs and drug development services at the park.”

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with China. With six offices strategically located in China, the most comprehensive Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach to pharmaceutical co-development between the U.S. and China. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and reduces complexity in making deals in China. The company has become a champion of guiding China‘s biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com.

ABOUT China medical city, Taizhou National Medical Hi-tech Development Zone

China Medical City (CMC) is located in Taizhou, a riverside city of Jiangsu Province in Yangtze Delta and hometown of Chinese President Mr. Hu Jintao. Established in 2005 as the first national level hi-tech park devoted to the pharmaceutical industry, CMC has received tremendous support from both the central and provincial governments. With a vision to develop into an internationally competitive center for medical R&D and commercialization, CMC is at the forefront of China‘s efforts to develop a streamlined pharmaceutical industry, concentrating all services and support for the medical industry in one location from R&D and government support services facilitating registrations and patent filing to manufacturing, distribution and comprehensive healthcare delivery. For more information, visit http://www.medmax.cn/.

SOURCE HUYA Bioscience International